Broadcast Date: 
  • Time: 

Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various cancers. However, progress remains slow due to several technical challenges in the ADC discovery and development process. In addition, the field has become increasingly competitive with several new players all going after the same target(s) or using the same or similar payload linkers. To accelerate their ADC discovery and development efforts, biopharmaceutical companies need novel tools that address bottlenecks in their pipelines and boost the efficacy of their therapy candidates.

In this GEN webinar Jiawei Lu, PhD, Head of Bioconjugation Discovery Service at WuXiXDC, will discuss strategies for accelerating ADC discovery and development using novel payload linkers and conjugation technologies. You’ll hear about WuXi XDC’s proprietary technologies for ADC discovery and development and how they help solve current challenges such as increasing ADC homogeneity to enhance PK and efficacy while lowering toxicity, and improving ADCs’ ability to penetrate and release their payload in tumors. Key topics that will be covered in the webinar include:

  • The current landscape of ADC pipelines and the major discovery and development challenges.
  • WuXi XDC’s proprietary technologies for increasing ADC homogeneity and more efficient conjugation.
  • How WuXi XDC’s integrated service platform can shorten the timeline and accelerate ADC discovery and development.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Jiawei Lu
Jiawei Lu, PhD
Head of Bio-Conjugation Discovery Services